By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Researchers detail new data in Biotechnology. According to news reporting out of Udine, Italy, by NewsRx editors, research stated, "Hepatocellular carcinoma (HCC) is the most frequent primary liver tumor, and overall, it is one of the most frequent cancers. The association of HCC with chronic liver disease, and cirrhosis in particular, is well known, making treatment complex and challenging."
Our news journalists obtained a quote from the research from the University of Udine, "The treatment of HCC must take into account the presence and stage of chronic liver disease, with the aim of preserving hepatic function that is often already impaired, the stage of HCC and the clinical condition of the patient. The different treatment options include surgical resection, transplantation, local ablation, chemoembolization, radioembolization and molecular targeted therapies; these treatments can be combined in various ways to achieve different goals. Ideally, liver transplantation is best treatment for early stage HCC on cirrhosis because it removes both the tumor and the chronic disease that produced it; however, the application of this powerful tool is limited by the scarcity of donors. Downstaging and bridging are different strategies for the management of HCC patients who will undergo liver transplantation. Several professionals, including gastroenterologists, radiologists and surgeons, are involved in the choice of the most appropriate treatment for a single case, and a multidisciplinary approach is necessary to optimize the outcome."
According to the news editors, the research concluded: "The purpose of this review is to provide a comprehensive description of the current treatment options for patients with HCC by analyzing the advantages, disadvantages and rationale for their use."
For more information on this research see: Multimodal treatment of hepatocellular carcinoma on cirrhosis: An update. World Journal of Gastroenterology, 2013;19(42):7316-7326. World Journal of Gastroenterology can be contacted at: Baishideng Publ Grp Co Ltd, Room 1701, 17-F, Henan Building, No. 90, Jaffe Rd, Wanchai, Hong Kong 100025, Peoples R China. (Baishideng Publishing Group - www.wjgnet.com/; World Journal of Gastroenterology - www.wjgnet.com/1007-9327/current.htm)
Our news journalists report that additional information may be obtained by contacting M. Vivarelli, University of Udine, Dept. of Surg & Transplantat, I-33100 Udine, Italy. Additional authors for this research include R. Montalti and A. Risaliti (see also Biotechnology).
Keywords for this news article include: Biotechnology, Udine, Italy, Europe, Surgery, Fibrosis, Oncology, Cirrhosis, Treatment, Cancer Gene Therapy, Liver Transplantation, Organ Transplantation, Tissue Transplantation, Hepatocellular Carcinoma, Digestive System Surgical Procedures
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC